cyrilzakka/clinical-trials huggingface dataset:
The Effect of Imagery Exercises on Attention and Performance in Olympic Archers

The goal of this clinical trial is to for beginners in archery in to examine the effects of Imagination and breathing exercises given in addition to 8-week archery training on archery target score, postural sway, attention, hand grip, visualization and respiratory function parameters.. The main questions it aims to answer are:

* Do Imagination and breathing exercises have an effect on archery target shooting score?
* Do breathing exercises positively affect shooting performance by reducing postural sway?
* Do archers' imagination skills positively affect their attention and performance?
* Do hand grip strength and reaction time positively affect shooting performance?

Participants will Routine exercises used in archery training will be applied to all participants.

Researchers will compare control group, Imagination group and meditation group to see if Control group (CG); Only routine exercise program will be applied. To the Imagination Group (IG); In addition to routine exercises, a 15-minute visualization session will be applied. Respiratory Group (SG); Breathing exercises will be applied in addition to routine exercises.


Eligibility Criteria:
Inclusion Criteria:

* Completing the study consent form,
* Successful in the The Closed Kinetic Chain Upper Extremity Stability Test (CKCUEST),
* Successful in the Upper Quarter Y Balance Test (YBT),
* Those who do archery sports were included in the study.

Exclusion Criteria:

* Having musculoskeletal system problems,
* Having a neurological disease,
* Having vestibular disease,
* Having pulmonary disease,
* Hearing loss,
* Those who have undergone orthopedic surgery will not be included in the study.
Small Sample，Unicentric，Randomized, Controlled Clinical Study of Coenzyme I for Injection in the Treatment of Sudden Sensorineural Hearing Loss

Sudden sensorineural hearing loss is one of the most common emergencies in otorhinolaryngology, and its incidence is increasing year by year and tends to be younger. At present, the pathogenesis of sudden deafness is not clear and the individual treatment effects vary significantly. In order to break through this specific treatment bottleneck, this project pioneered the clinical application of the co-regulator nicotinamide adenine dinucleotide (NAD+) in the treatment of sudden deafness. Therefore, this project intends to use pure tone audiometry, speech audiometry, tinnitus disability scale THI, tinnitus subjective visual analog score method VAS, ear fullness subjective visual analog score method VAS for data analysis, and explore the safety of coenzyme I for injection on sudden deafness and efficacy assessment.

The recruited participants were patients with sudden hearing deafness, and the basic demographic data, including name, gender, age, medical history, etc., were collected. According to the inclusion and exclusion criteria, the patients were randomly divided into the experimental group and the control group. The experimental group was given conventional treatment + coenzyme I for injection, and the control group was given conventional treatment for 14 days. Baseline data were collected before treatment, and post-treatment data were collected on 3d, 7d, 14d，1m and 3m of treatment. Baseline data and post-treatment data included pure tone audiometry, speech audiometry, tinnitus THI scale, tinnitus VAS scale, tinnitus Stupid VAS scale.

Eligibility Criteria:
Inclusion Criteria:

1. Age ≥18yrs.the 2019 American Sudden Deafness Guidelines are for patients with sudden deafness over 18 years of age;
2. Patients diagnosed with sudden deafness, i.e. unexplained sensorineural hearing loss occurring within 72 hours, with hearing threshold ≥30 in at least 3 consecutive frequencies, refer to the 2019 American Sudden Deafness Guidelines;
3. Unilateral sudden deafness;
4. Within 1 week of the onset of sudden deafness, no treatment in another hospital/our hospital;
5. No major neurological disease, serious systemic disease, family genetic history, major mental illness;
6. Informed and agreed to join the experiment, no plan to move out or go out within 1 month.

Exclusion Criteria:

1. Other diseases such as acoustic neuroma diagnosed by imaging;
2. Those who cannot tolerate NAD+;
3. pregnant；
4. Any other circumstances that the investigator believes should be excluded from this study；
5. Do not agree to join the experiment, plan to move out or go out within 1 month.
Immunology and Safety of Menactra® in Children in Saudi Arabia

This study will be conducted among children in Saudi Arabia who previously received two doses of A, C, Y, W-135 polysaccharide vaccine before the age of 2 years, and in meningococcal vaccine-naïve children (Control Group). This study will evaluate the administration of Menactra® in terms of the serum bactericidal antibody it induces in the two study groups. Safety of Menactra® vaccine will be described.


Eligibility Criteria:
Inclusion Criteria :

* Healthy, as determined by medical history and physical examination.
* Aged between 5 to 8 years on the day of inclusion (from 5th birthday to 1 day before 9th birthday inclusive).
* For the Booster Group , two doses of a quadrivalent (A, C, Y, W-135) meningococcal polysaccharide vaccine received before age 2 years
* For the Control Group , no previous history of any meningococcal vaccination
* Informed consent form signed by the parent(s) or other legal representative
* Able to provide a vaccination log or has available vaccination record in the Health Center.
* Able to attend all scheduled visits and to comply with all trial procedures

Exclusion Criteria :

* Serious chronic disease (i.e., cardiac, renal, neurologic, metabolic, rheumatologic, psychiatric, etc.)
* Known or suspected impairment of immunologic function.
* Acute medical illness with or without fever within the last 72 hours or a oral temperature ≥ 37.5°C at the time of inclusion.
* Administration of immune globulin or other blood products within the last three months, injected or oral corticosteroids or other immunomodulatory therapy within six weeks of the trial vaccine. Individuals on a tapering dose schedule of oral steroids lasting \< 7 days may be included in the trial provided that they have not received more than one course within the last two weeks prior to enrollment.
* Oral or injected antibiotic therapy within the 72 hours prior to vaccination.
* Received any vaccine in the 14-day period prior to trial vaccination, or scheduled to receive any vaccination during the 14-day period after trial vaccination.
* Previous history of documented invasive meningococcal disease.
* For the Control Group, previous history of any meningococcal vaccination.
* Systemic hypersensitivity to any of the vaccines components or history of a life-threatening reaction to the trial vaccines or a vaccine containing the same substances.
* Participation in another clinical trial in the 4 weeks preceding the trial vaccination
* Planned participation in another clinical trial during the present trial period
* Any condition, which, in the opinion of the investigator, would pose a health risk to the subject, or interfere with the evaluation of the vaccine.
* Personal or family history of Guillain Barré syndrome.
Phase II Study of Fluconazole for Lymphocutaneous and Visceral Sporotrichosis

OBJECTIVE:

I. Evaluate the efficacy of fluconazole in patients with lymphocutaneous or visceral sporotrichosis.

PROTOCOL OUTLINE:

Patients are treated with daily oral fluconazole for up to 24 months. Follow-up continues for at least 1 year.

Eligibility Criteria:
PROTOCOL ENTRY CRITERIA:

--Disease Characteristics-- Presumptive evidence of sporotrichosis Culture-proven sporotrichosis determined on study Relapsing disease following antifungal therapy eligible if culture positive for Sporothrix schenckii prior to entry No life-threatening disease No central nervous system sporotrichosis --Prior/Concurrent Therapy-- No concurrent drugs known to react with fluconazole No more than 3 days of systemic antifungals for current sporotrichosis episode --Patient Characteristics-- Hepatic: Liver function tests no greater than 5 times normal Other: No HIV infection No pregnant or nursing women
Increasing Exercise and Decreasing Sedentary Behavior Among Patients in a Cardiac Rehabilitation Clinic

Cardiac rehabilitation patients often fail to exercise as prescribed on days they are not attending rehabilitation and there is a steep drop off in exercise following rehabilitation completion. Moreover, little is known about the amount of time that cardiac rehabilitation patients spend in sedentary behavior, which is associated with increased risk of cardiovascular morbidity and mortality, independent of time spent in exercise. This pilot study aims to test acceptability, feasibility, and preliminary efficacy of a smartphone application (B-MOBILE-CARDIAC) for increasing time spent in moderate-to-vigorous intensity physical activity accumulated in bouts of at least 10 minutes in duration (i.e. bout-related MVPA) and decrease time spent in sedentary behavior. Up to 32 patients will be recruited, enrolled, and randomized during the first 2 weeks of cardiac rehabilitation to either: 1) B-MOBILE-CARDIAC plus cardiac rehabilitation or 2) cardiac rehabilitation alone. Participants will complete 7 days of objective activity monitoring to measure daily minutes spent in bout-related MVPA and sedentary behavior (primary outcomes) at baseline, mid-rehabilitation (6 weeks), end of cardiac rehabilitation (12 weeks), and 4-week follow-up (16 weeks). At these same time points, participants will complete questionnaires assessing sedentary behavior, MVPA, exercise tolerance, health-related quality of life, mood, and affect. At baseline and end of cardiac rehabilitation participants will undergo a blood draw to measure cardiometabolic and inflammatory risk factors and complete a test of cognitive functioning. Feasibility and acceptability of the B-MOBILE-CARDIAC application will be assessed at the 4-week follow-up.


Eligibility Criteria:
Inclusion Criteria:

1. within one week of starting rehabilitation,
2. self-report that they can walk for 10 minutes without assistance from others,
3. were approved for and are planning to complete 12 weeks of rehabilitation,
4. own a compatible Android phone or are willing to be taught to use one by study staff;
5. no evidence of cognitive impairment
6. able to speak and read English,
7. aged 18-75 years,
8. no known nickel allergy, and
9. willing to follow the protocol (e.g., carry a smartphone for 16 weeks).

Exclusion Criteria:

-
Targeting Methods of Botulinum Toxin Injections for Cervical Dystonia

Botulinum toxin injections are the treatment of choice for cervical dystonia. Even if this treatment is successful for most of the patients, partials or completes failures still remained.

Usually, botulinum toxin injections are realized by clinical localization techniques (observation and palpation of target muscles). The use of Ultrasonography to guide injections of Botulinum toxin has theoretical benefits (as an improved precision, an improved reproducibility, the targeting of deep-seated muscles, and a lower risk of adverse events) but its interest has never been demonstrated.

Open label non-randomised controlled clinical trial comparing clinical localization techniques and ultrasonography to guide injections of Botulinum toxin A.

The primary outcome is to compare both techniques of injection regarding to the health impact of cervical dystonia (CDIP-58) measured 1 month after injection.

The results of this clinical trial will help the clinician to decide which strategy of injection is the most effective in terms of benefit/risk ratio to treat the cervical dystonia.

Eligibility Criteria:
Inclusion Criteria:

* Patient older than 18 years old
* Focal idiopathic cervical dystonia treated by injections of Botulinum toxin type A (onabotulinumtoxinA, Botox® ; abobotulinumtoxinA, Dysport® ; or incobotulinumtoxinA, Xeomin®).
* Patient who have previously received at least 3 cycles of botulinum toxin A injections in this specific indication
* Injections realized with clinical targeting exclusively or ultrasonography targeting exclusively
* Patient who is not opposed to its participation in this study
* Patient affiliated to the Sécurité Sociale
* Patient able to comply with study procedures and study duration

Exclusion Criteria:

* Woman pregnant, woman of childbearing age not taking effective contraception or breastfeeding
* Contraindication of botulinum toxin injections as :

  * Hypersensivity to the botulinum toxin A or to an excipient of the commercialized treatment (onabotulinumtoxinA, Botox® ; abobotulinumtoxinA, Dysport® ; incobotulinumtoxinA, Xeomin®)
  * Generalized muscular activity disorder (Myasthenia gravis, Lambert-Eaton syndrome)
  * Infection or inflammation of the injection site
* Concomitant treatment that can interact with botulinum toxin A or modify the function of the neuromuscular synapse junction (anticholinergics, curare and other myorelaxing agents, Aminoglycosides, amino-4-quinolines)
* Documented resistance to the botulinum toxin A
* Inability to receive the information, inability to participate to the all study duration, refusal to sign the consent
* EMG-guided botulinum toxin injections
Monitoring of Syncopes and/or Sustained Palpitations of Suspected Arrhythmic Origin With External Loop-Recorder (SpiderFLASH)

The purpose of this study is to evaluate the diagnostic yield (at 1 month post enrollment) of an external loop recorder (SpiderFlash-T) in patients with syncope or palpitations of suspected arrhythmic origin, within 30 days before enrollment.

Diagnostic yield (primary outcome) definition = Number of patients with conclusive diagnosis (as per investigators' decision) over the total number of patients

Eligibility Criteria:
Inclusion Criteria:

* Syncope and/or palpitations events occurred in the last 30 days
* Events likely of arrhythmic origin
* No conclusive diagnosis established yet
* High probability of episodes recurrence (presence of at least one previous event in the last 12 months)
* Patient has signed the consent to participate to the study and/or to data treatment

Exclusion Criteria:

* Inability to understand the purpose of the study or refusal to cooperate
* Expected low compliance with the recording technique.
* Logistical impossibility to deliver the ELR within 30 days after the index event (or after discharge from ER and/or hospitalization and/or clinic visit)
* Already included in other competitor clinical study
* Under guardianship
* Age less than 18
Video-based Counseling & Rapid HIV Testing for Teens

This study evaluated the educational effectiveness of a youth-friendly pre-test video (derived from a previous qualitative study) and compared it with in-person HIV pre-test counseling. A convenience sample of 200 medically stable individuals between the ages of 15 and 21 presenting to an urban ED were recruited to participate in this study and randomized into 2 groups. Individuals were eligible if they were English-speaking, sexually active and able to consent. All participants completed a sexual risk factor and demographic survey. Group 1 completed a validated pre-test knowledge measure, viewed the HIV education video then completed a post-test knowledge measure. Group 2 completed the same knowledge measures, but received pre-test HIV counseling from a trained public health advocate. HIV testing was optional


Eligibility Criteria:
Inclusion Criteria:

* 15-21 year old
* sexually active
* English-Speaking

Exclusion Criteria:

* medically unstable
Beetroot Juice Supplementation in Basketball Players

Whereas beetroot juice (BJ) supplementation is shown to increase physical performance in endurance activities, its benefits in team sports has been barely studied. In this randomized placebo-controlled study, we investigated the effects of BJ acute supplementation in improving neuromuscular performance and physical match activity in basketball.

Whereas beetroot juice (BJ) supplementation is shown to increase physical performance in endurance activities, its benefits in team sports has been barely studied. In this randomized placebo-controlled study, we investigated the effects of BJ acute supplementation in improving neuromuscular performance and physical match activity in basketball.Testing sessions will comprised a neuromuscular test battery consisting of a countermovement jump (CMJ), isometric handgrip strength, 10-m/20-m sprint and agility T-test, followed by a 40-minute simulated basketball match. Physical match activity (distances, speeds, accelerations and decelerations) will be monitored in real time using an inertial tracking system

Eligibility Criteria:
Inclusion Criteria:

* active basketball player
* more than 5 years of basketball training experience

Exclusion Criteria:

* concurrently participating in other studies
* contraindications to BJ diet
* physical limitations, health problems, or musculoskeletal injuries
CLAIR -FO: Clinical Trial of Ophthalmic Insert Mydriasert® Versus Reference Treatment

Pupillary dilation to perform a fundus in premature newborns and neonates is often difficult to obtain, because of the non mature iris sphincter. The fundus is essential to detect retinal anomalies (as retinopathy of prematurity or chorioretinal or disk anomalies). The aim of the study is to obtain a satisfactory degree of mydriasis with a minimal dose of two mydriatic treatments, with an optimal duration and a good tolerance of the drugs. The study will evaluate the mydriasis in premature newborns, neonates and infants justifying a mydriasis for a bilateral diagnosis fundus, using ophthalmic insert Mydriasert® versus reference treatment (association of phenylephrine and tropicamide eyedrops). Ophthalmic insert Mydriasert® can control drug dispensation and decrease the number of nurse interventions to obtain mydriasis in patients.

The aim of the study is to obtain a satisfactory degree of mydriasis with a minimal dose of two mydriatic treatments, with an optimal duration and a good tolerance of the drugs. The study will evaluate the mydriasis in premature newborns, neonates and infants justifying a mydriasis for a bilateral diagnosis fundus, using ophthalmic insert Mydriasert® versus reference treatment (association of phenylephrine and tropicamide eyedrops). Ophthalmic insert Mydriasert® can control drug dispensation and decrease the number of nurse interventions to obtain mydriasis in patients.

Eligibility Criteria:
Inclusion Criteria:

* Premature newborns, neonates and infants of less 18 months-old indoor in the neonatology clinical department of Robert Debre Hospital with cardiologic monitoring
* Presenting a risk of retinopathy of prematurity or fundus anomaly (chorioretinal and/or disk anomalies).
* Needing a bilateral fundus
* Parents, tutor or legal representing of the patient had been informed of objectives of the study and had given their written consent.
* Covered by French social security or CMU

Exclusion Criteria:

* Neonates of less 1000g at inclusion
* Premature newborn of less 30 weeks of gestational age at inclusion
* Contra-indication to one of the evaluated drugs
* Any treatment that could provoke a dangerous drug interaction for the patient if associated with one of the drug of the study
* Anatomical predisposition to glaucoma, hypertension or any other contra-indication noted by the physician
PREdiction of DIagnosed Covid-19 infecTion in IUC Patients

Coronavirus 2019 (COVID-19) is a respiratory tropism virus transmitted through droplets emitted into the environment of infected persons. The symptoms can be extremely varied and the course can range from spontaneous healing without sequelae to death.

Currently, the diagnosis of certainty for resuscitation patients (by definition "severe") is based on searching for a fragment of virus genetic material within the epithelial cells of the respiratory tree, up and/or down, by PCR.

It is to be expected that the epidemic peak will make it difficult (if not impossible) to respect the stereotypical path that is currently in place, due to the lack of space in the specific unit. This will require optimization of care pathways and use of the specific sectors.

It is therefore necessary to define the simple criteria, available from the moment patients are admitted, to predict the result of the COVID-19 PCR.


Eligibility Criteria:
Inclusion Criteria:

* All patient admitted in ICU Lille Hospital and hospitalized in the unit "Emergent Biological Risk" (REB) before a suspicion of infection with COVID-19
* Clinical infectious syndrome: fever (\>38°C) or hypothermia ( 36°C), chill, fever at home
* a severe respiratory table defined by:
* Oxygen demand \> 3 L/min in the presence of significant comorbidity (pregnancy, chronic respiratory disease, chronic heart disease, hemopathy, cirrhosis) or \> 6 L/min in the absence of comorbidity
* or a respiratory rate \> 30 cycles per minute
* the need for mechanical, invasive or non-invasive ventilation
* the need for humidified high-flow oxygen therapy

Exclusion Criteria:

* Patient already included in study for first stay
* Cirrhosis CHILD C
* Major surgery in the last 7 days Minor patient
* Patient under guardianship or curatorship
* Refusal to participate
* No social security coverage.
Evaluation of Endothelial Dysfunction During Aortic Valvular Replacement by Bioprosthesis With and Without Extracorporeal Circulation

Patients with aortic stenosis present many risk factors for endothelial dysfunction (arterial hypertension, arteriosclerosis, dyslipidemia, chronic renal insufficiency, etc.). It is likely that a significant number of patients suffer from pre-existing endothelial dysfunction that can be evaluated by a molecular approach.

To date, the replacement of the aortic valve can be performed by surgery with extracorporeal circulation (CEC) or percutaneous (Transcatheter Aortic Valve ImplantationTAVI) without CEC.

Two recent studies have demonstrated a sustained improvement in endothelial function with TAVI. On the contrary, studies have demonstrated that post-operative complications (coagulopathy, capillary leak syndrome, acute vasoplastic disorder and acute renal failure) after surgery with extracorporeal circulation (CEC) could be the result of the interaction between pre-existing endothelial dysfunction And the "operative" aggression associated with the CEC.

Thus, patients with preexisting involvement of endothelial function would develop vascular dysfunction after valvular replacement due to "endothelial activation" related to CEC. This phenomenon would not exist in TAVI, and would explain the absence of so-called vascular dysfunction complications (Systemic inflammatory response syndrome, vasoplastic syndrome, disseminated intravascular coagulation).


Eligibility Criteria:
Inclusion Criteria:

* Patient ≥ 18 years.
* Patient operated on aortic valvular replacement by bioprosthesis in surgery + CEC or TAVI
* Signed consent.
* Affiliation to Social Security

Exclusion Criteria:

* Any other cardiac surgery
* Mechanical aortic valve replacement
* Permanent Ac / Fa.
* Pregnant woman.
* Curative anticoagulation (AVK, NANCO, heparin).
* Patient under tutelage or curatelle.
* Refusal of the patient.
* Participation in another study.
* Preoperative sepsis
* Minor or adult, under guardianship or curatorship